{"id":"https://openalex.org/W2944251997","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","title":"Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer","display_name":"Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer","publication_year":2019,"publication_date":"2019-02-15","ids":{"openalex":"https://openalex.org/W2944251997","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","mag":"2944251997"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs18-p6-18-10","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022582448","display_name":"Shom Goel","orcid":"https://orcid.org/0000-0001-8329-9084","observed_orcids":["https://orcid.org/0000-0001-8329-9084"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Goel","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064315491","display_name":"LM Spring","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L Spring","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017140112","display_name":"Rebecca Rees","orcid":"https://orcid.org/0000-0003-1691-0335","observed_orcids":["https://orcid.org/0000-0003-1691-0335"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R Rees","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056944911","display_name":"Chelsea Andrews","orcid":"https://orcid.org/0000-0002-7292-5788","observed_orcids":["https://orcid.org/0000-0002-7292-5788"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C Andrews","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109157214","display_name":"RK Tahara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"RK Tahara","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073728088","display_name":"Erica L. Mayer","orcid":"https://orcid.org/0000-0001-5430-8957","observed_orcids":["https://orcid.org/0000-0001-5430-8957"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"EL Mayer","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A Bardia","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"EP Winer","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"SM Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"4_Supplement","first_page":"P6","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8809000253677368,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.8809000253677368,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.11219999939203262,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribociclib","display_name":"ribociclib","score":0.9879999756813049},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9750000238418579},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8539999723434448},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.6169999837875366},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.6800000071525574},{"id":"https://openalex.org/keywords/refractory-disease","display_name":"refractory disease","score":0.8180000185966492},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6899999976158142},{"id":"https://openalex.org/keywords/clinical-benefit-rate","display_name":"clinical benefit rate","score":0.6039999723434448},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6919999718666077},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8980000019073486},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5559999942779541},{"id":"https://openalex.org/keywords/qtc-prolongation","display_name":"QTc prolongation","score":0.6179999709129333},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.5799999833106995},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.5910000205039978},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.8659999966621399}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9021353721618652},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.8468396663665771},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.7504855990409851},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6452792882919312},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6304962635040283},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5922415256500244},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5844300985336304},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5515956878662109},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.5228967070579529},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.47569024562835693},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4410708248615265},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3301853537559509},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs18-p6-18-10","doi":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947157601","https://openalex.org/W2623866550","https://openalex.org/W7162546848","https://openalex.org/W2947241004","https://openalex.org/W3190199458","https://openalex.org/W4410804846","https://openalex.org/W3135762584","https://openalex.org/W3137610496","https://openalex.org/W2740422606","https://openalex.org/W2886656453"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Despite":[2],"the":[3,13,32,55,75,87,142,235,258,264,292,306,491,503],"success":[4],"of":[5,25,34,54,74,144,147,217,365,390,393,409,420,486,493,502],"anti-HER2":[6],"therapy,":[7],"acquired":[8],"resistance":[9],"usually":[10],"develops":[11],"in":[12,29,227,257,263,284,314,440],"metastatic":[14,135,244,397,410],"setting.":[15],"CDK4/6":[16,35,56,152,451],"pathway":[17],"activity":[18,374,438],"has":[19],"been":[20],"identified":[21],"as":[22,132],"a":[23,49,195,205,457],"mediator":[24],"this":[26,441],"resistance,":[27],"and":[28,36,95,106,130,189,249,261,275,296,318,322,325,356,422],"preclinical":[30],"studies":[31],"combination":[33,419],"HER2":[37],"blockade":[38],"can":[39],"be":[40,454],"more":[41,232],"effective":[42],"than":[43],"either":[44],"therapy":[45,395],"alone.":[46],"We":[47],"conducted":[48],"single-arm":[50],"phase":[51,171,483],"1b/2":[52,484],"study":[53,203,366,485],"inhibitor":[57,153],"ribociclib":[58,190,297,379,423,487],"given":[59],"with":[60,66,111,150,240,378,402,430],"trastuzumab":[61,76,182,363,421,489],"or":[62,114,134,160,337],"T-DM1":[63,131,377],"to":[64,85,229,234,271,371,449,456],"subjects":[65,123,179],"advanced,":[67,494],"treatment-refractory":[68,495],"HER2-positive":[69,117,496],"breast":[70,118,497],"cancer.":[71],"The":[72,81,202,208,362,418,436],"results":[73],"cohort":[77,380],"are":[78,282],"presented":[79],"below.":[80],"primary":[82],"objective":[83,99,352],"was":[84,138,269,298,359,367],"determine":[86],"clinical":[88,222,373],"benefit":[89,223],"rate":[90,101],"(CBR)":[91],"at":[92,214,247,301],"24":[93],"weeks,":[94],"secondary":[96],"endpoints":[97],"included":[98,177,319],"response":[100],"(ORR),":[102],"progression-free":[103],"survival":[104],"(PFS),":[105],"adverse":[107],"events.":[108],"Methods:":[109],"Individuals":[110],"locally":[112],"advanced":[113],"metastatic,":[115],"measurable":[116],"cancer":[119,498],"were":[120,165,254,289,312,354],"eligible.":[121],"All":[122,238],"must":[124,219],"have":[125,220,272],"previously":[126],"received":[127,181],"trastuzumab,":[128],"pertuzumab,":[129],"(neo)adjuvant":[133],"therapy.":[136],"There":[137],"no":[139,351,431],"limit":[140],"on":[141,158,194],"number":[143],"prior":[145,391],"lines":[146,392],"treatment.":[148,279],"Patients":[149],"previous":[151],"exposure,":[154],"QTcF":[155],">":[156],"450msec":[157],"EKG,":[159],"without":[161],"stable":[162,348],"brain":[163],"metastases":[164],"excluded.":[166],"An":[167],"initial":[168],"safety":[169,259,293,433],"run-in":[170,260,294],"(with":[172],"dose-limiting":[173],"toxicity":[174],"(DLT)":[175],"monitoring)":[176],"six":[178],"who":[180],"(8mg/kg":[183],"loading":[184],"then":[185],"6mg/kg":[186],"IV":[187],"three-weekly)":[188],"400mg":[191,302],"PO":[192],"daily":[193,304,425],"continuous":[196,426],"schedule":[197],"(cycle":[198],"length":[199],"21":[200],"days).":[201],"had":[204],"two-stage":[206],"design.":[207],"first":[209],"stage":[210],"required":[211],"20":[212],"patients,":[213],"least":[215],"6":[216],"whom":[218],"demonstrated":[221,332],"(CR+PR+":[224],"SD>24":[225],"weeks)":[226],"order":[228],"recruit":[230],"15":[231],"patients":[233,239,253,316,342],"second":[236],"stage.":[237],"accessible":[241],"disease":[242,274,398,405],"underwent":[243],"tumor":[245],"biopsies":[246],"baseline":[248],"C2D1.":[250],"Results:":[251],"13":[252],"enrolled":[255],"(6":[256],"7":[262],"expansion":[265,307],"cohort).":[266],"One":[267],"patient":[268,331],"found":[270],"HER2-negative":[273],"did":[276],"not":[277],"receive":[278],"Patient":[280],"characteristics":[281],"shown":[283],"Table":[285,383],"1":[286],"No":[287,330],"DLTs":[288],"observed":[290,313,375],"during":[291],"phase,":[295],"thus":[299],"used":[300],"po":[303],"for":[305,396,490],"cohort.":[308],"Grade":[309],"3/4":[310,339],"toxicities":[311],"5":[315],"(41.7%)":[317],"neutropenia":[320],"(n=2),":[321],"fatigue,":[323],"pain,":[324],"muscle":[326],"weakness":[327],"(all":[328],"n=1).":[329],"QTc":[333],"prolongation":[334],">480":[335],"msec,":[336],"grade":[338],"LFTs.":[340],"1/12":[341],"((8.3%);":[343],"95%":[344],"CI":[345],"0.2%-38.5%)":[346],"achieved":[347],"disease>24":[349],"weeks;":[350],"responses":[353],"observed,":[355],"median":[357],"PFS":[358],"41.5":[360],"days.":[361],"portion":[364],"closed":[368],"early":[369],"due":[370],"limited":[372,437,455],"(the":[376],"remains":[381],"open).":[382],"1Age":[384],"(median,":[385,399,412],"range)50.5":[386],"(42":[387],"-":[388,415],"71)Number":[389],"systemic":[394],"range)5.5":[400],"(0-14)Number":[401],"Hormone":[403],"receptor-positive":[404],"(%)8":[406],"(67":[407],"%)Number":[408],"sites":[411],"range)2.5":[413],"(2":[414],"5)":[416],"Conclusions:":[417],"(400mg":[424],"schedule)":[427],"is":[428],"safe,":[429],"new":[432],"signals":[434],"observed.":[435],"seen":[439],"heavily":[442],"pretreated":[443],"population":[444],"suggests":[445],"that":[446],"future":[447],"efforts":[448],"incorporate":[450],"inhibition":[452],"should":[453],"less":[458],"extensively":[459],"treat":[460],"population.":[461],"Citation":[462],"Format:":[463],"Goel":[464],"S,":[465],"Spring":[466],"L,":[467],"Rees":[468],"R,":[469],"Andrews":[470],"C,":[471],"Tahara":[472],"RK,":[473],"Mayer":[474],"EL,":[475],"Bardia":[476],"A,":[477],"Winer":[478],"EP,":[479],"Tolaney":[480],"SM.":[481],"A":[482],"plus":[488],"treatment":[492],"[abstract].":[499],"In:":[500],"Proceedings":[501],"2018":[504,510],"San":[505,513],"Antonio":[506],"Breast":[507],"Cancer":[508,519],"Symposium;":[509],"Dec":[511],"4-8;":[512],"Antonio,":[514],"TX.":[515],"Philadelphia":[516],"(PA):":[517],"AACR;":[518],"Res":[520],"2019;79(4":[521],"Suppl):Abstract":[522],"nr":[523],"P6-18-10.":[524]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2019-05-16T00:00:00"}